BIAF Stock Price, bioAffinity Technologies, . Quote, Chart

Market Summary

USD2.42+0.01

Market Closed

0.41%

BIAF Stock Price

View Fullscreen

BIAF RSI Chart

BIAF Valuation

Market Cap

27.9M

Price/Earnings (Trailing)

-3.51

Price/Sales (Trailing)

11

EV/EBITDA

-3.29

Price/Free Cashflow

-4.6

BIAF Price/Sales (Trailing)

BIAF Profitability

Operating Margin

99.98%

EBT Margin

-312.58%

Return on Equity

-163.47%

Return on Assets

-96.54%

Free Cashflow Yield

-21.75%

BIAF Fundamentals

BIAF Revenue

Revenue (TTM)

2.5M

Rev. Growth (Yr)

21.1K%

Rev. Growth (Qtr)

641.53%

BIAF Earnings

Earnings (TTM)

-7.9M

Earnings Growth (Yr)

-41.72%

Earnings Growth (Qtr)

-3.59%

Breaking Down BIAF Revenue

Last 7 days

-12.9%

Last 30 days

16.4%

Last 90 days

47.6%

How does BIAF drawdown profile look like?

BIAF Financial Health

Current Ratio

1.77

BIAF Investor Care

Shares Dilution (1Y)

36.05%

Diluted EPS (TTM)

-0.5

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	0	847.4K	1.7M	2.5M
2022	0	0	0	4.8K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of bioAffinity Technologies, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 08, 2024	zannes maria	sold (taxes)	-74,899	2.65	-28,264	president & ceo
Apr 08, 2024	zannes maria	acquired	75,223	1.16	64,848	president & ceo
Apr 04, 2024	zannes timothy p	acquired	75,223	1.16	64,848	secretary, evp, gen. counsel
Apr 04, 2024	zannes timothy p	sold (taxes)	-74,900	2.58	-29,031	secretary, evp, gen. counsel
Apr 03, 2024	girgenti steven	acquired	75,223	1.16	64,848	-
Apr 03, 2024	girgenti steven	sold (taxes)	-74,901	2.24	-33,438	-
Feb 26, 2024	anderson robert a.	acquired	74,899	1.155	64,848	-
Feb 16, 2024	girgenti steven	acquired	60,000	1.52	39,474	executive chairman
Jan 31, 2024	zannes maria	acquired	-	-	23,885	president, ceo
Jan 31, 2024	girgenti steven	acquired	-	-	11,943	executive chairman

Which funds bought or sold BIAF recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Mar 11, 2024	VANGUARD GROUP INC	unchanged	-	6,134	29,410	-%
Feb 14, 2024	STATE STREET CORP	unchanged	-	4,752	26,224	-%
Feb 14, 2024	BANK OF AMERICA CORP /DE/	new	-	8.00	8.00	-%
Feb 14, 2024	CLEAR STREET LLC	unchanged	-	-	2,000	-%
Feb 14, 2024	Creative Planning	unchanged	-	3,710	17,786	-%
Feb 14, 2024	CAPTRUST FINANCIAL ADVISORS	reduced	-8.61	7,860	58,651	-%
Feb 14, 2024	SUSQUEHANNA INTERNATIONAL GROUP, LLP	sold off	-100	-961	-	-%
Feb 14, 2024	TWO SIGMA INVESTMENTS, LP	unchanged	-	6,638	31,825	-%
Feb 14, 2024	CITADEL ADVISORS LLC	reduced	-5.2	334	2,682	-%
Feb 13, 2024	Qube Research & Technologies Ltd	unchanged	-	11.00	57.00	-%

Are Funds Buying or Selling BIAF?

Are funds buying BIAF calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own BIAF

No. of Funds

Recent SEC filings of bioAffinity Technologies, Inc.

View All Filings

Date Filed	Form Type	Document
Apr 24, 2024	4	Insider Trading
Apr 24, 2024	4	Insider Trading
Apr 24, 2024	4	Insider Trading
Apr 17, 2024	424B3	Prospectus Filed
Apr 15, 2024	EFFECT	EFFECT
Apr 15, 2024	ARS	ARS
Apr 15, 2024	DEF 14A	DEF 14A
Apr 15, 2024	DEFA14A	DEFA14A
Apr 05, 2024	POS AM	POS AM
Apr 05, 2024	EFFECT	EFFECT

Peers (Alternatives to bioAffinity Technologies, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
DHR	182.5B	23.7B	-0.93%	6.50%	41.46	7.69	-8.94%	-35.72%
IDXX	41.5B	3.7B	-7.44%	3.05%	49.1	11.33	8.72%	24.44%
A	40.3B	6.7B	-6.59%	3.31%	32.64	5.99	-2.81%	-6.58%
DGX	14.9B	9.3B	2.40%	-4.82%	17.61	1.6	-3.29%	6.68%
MEDP	12.3B	2.0B	-1.91%	100.24%	39.22	6.24	25.57%	21.62%
CRL	11.8B	4.1B	-15.01%	24.62%	24.77	2.85	3.86%	-2.39%
NTRA	11.1B	1.1B	1.32%	82.46%	-25.45	10.22	31.99%	20.63%
EXAS	10.7B	2.5B	-11.98%	-7.20%	-52.35	4.28	19.93%	67.26%
MID-CAP
NEOG	2.6B	929.2M	-21.41%	-29.07%	1.7K	2.83	28.93%	111.61%
GH	2.1B	563.9M	-3.40%	-19.97%	-4.4	3.74	25.45%	26.76%
SMALL-CAP
CDNA	390.9M	280.3M	-28.23%	-2.96%	-2.05	1.39	-12.89%	-148.37%
ACRS	84.4M	31.2M	-5.56%	-86.21%	-0.95	2.7	5.03%	-1.81%
APDN	74.4M	9.0M	918.60%	338.04%	-10.29	8.27	-53.31%	2.21%
AWH	41.1M	9.2M	-2.92%	-32.04%	-2.46	4.49	11.85%	44.12%
BIOC	183.8K	25.9M	-50.00%	-94.83%	-0.01	0.01	-57.78%	-93.11%

bioAffinity Technologies, Inc. News

Latest updates

bioAffinity Technologies, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2022Q4	2022Q3	2022Q2
Revenue	641.5%	2,213,356	298,484	19,738	10,444	1,150	1,306
Cost Of Revenue	-100.0%	-	74,704	1,234	-	146	146
Gross Profit	-100.0%	-	223,780	18,504	-	1,004	1,160
Operating Expenses	83.9%	4,631,786	2,518,284	1,796,854	1,625,912	977,160	685,279
S&GA Expenses	8.3%	2,192,328	2,023,917	1,426,469	1,379,785	595,702	408,620
R&D Expenses	40.7%	464,882	330,376	335,125	244,078	319,744	248,419
EBITDA Margin	27.4%	-3.01	-4.15	-10.40	-1,167	-	-
Interest Expenses	188.3%	25,325	8,785	1,360	89,290	896,502	399,265
Income Taxes	0.0%	2,293	2,294	4,587	-1.00	300	-
Earnings Before Taxes	-3.6%	-2,370,871	-2,288,590	-1,735,586	-1,674,583	-4,919,158	-88,052
EBT Margin	26.8%	-3.13	-4.27	-11.62	-1,697	-	-
Net Income	-3.6%	-2,373,164	-2,290,884	-1,740,173	-1,674,583	-4,919,458	-88,052
Net Income Margin	26.8%	-3.13	-4.28	-11.64	-1,697	-	-
Free Cashflow	-4.6%	-1,602,861	-1,532,682	-1,363,810	-	-	-

Balance Sheet

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Balance Sheet							(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2021Q4
Assets	-19.3%	8,222	10,189	8,873	10,465	12,182	14,063	1,453
Current Assets	-33.9%	3,973	6,010	8,659	10,233	11,962	14,055	1,438
Cash Equivalents	-37.8%	2,800	4,500	8,279	9,800	11,414	13,498	1,361
Inventory	86.6%	18.00	10.00	10.00	11.00	6.00	6.00	-
Net PPE	-10.4%	459	512	207	225	214	2.00	5.00
Goodwill	22.3%	1,404	1,149	-	-	-	-	-
Liabilities	5.3%	3,366	3,196	775	796	1,139	1,464	13,200
Current Liabilities	14.8%	2,248	1,959	775	796	1,139	1,464	13,040
Shareholder's Equity	-30.6%	4,855	6,994	8,098	9,668	11,043	12,599	-15,790
Retained Earnings	-5.6%	-44,604	-42,231	-39,940	-38,200	-36,667	-35,000	-28,513
Additional Paid-In Capital	0.5%	49,394	49,161	47,979	47,809	47,652	47,533	12,704
Shares Outstanding	1.9%	9,395	9,217	8,478	8,463	8,381	4,204	2,677

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)										(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3
Cashflow From Operations	-5.5%	-1,616	-1,532	-1,359	-1,529	-1,300	-1,760	-376	-633	-	-
Share Based Compensation	25.8%	235	186	170	158	37.00	79.00	27.00	106	-	-
Cashflow From Investing	100.6%	13.00	-2,186	-3.86	-32.31	-	-	-	-	-	-
Cashflow From Financing	-67.0%	-84.80	-50.77	-126	-83.32	-563	15,044	-437	301	-	-

BIAF Income Statement

2023-12-31

Consolidated Statements of Operations - USD ($)	12 Months Ended
Consolidated Statements of Operations - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Income Statement [Abstract]
Net Revenue	$ 2,532,499	$ 4,803
Operating expenses:
Direct costs and expenses	1,740,884	467
Research and development	1,467,936	1,378,624
Clinical development	256,661	145,546
Selling, general and administrative	6,790,654	2,481,042
Depreciation and amortization	249,592	10,182
Total operating expenses	10,505,727	4,015,861
Loss from operations	(7,973,228)	(4,011,058)
Other income (expense):
Interest income	122,131	46,708
Interest expense	(37,125)	(2,532,640)
Other Income	3,325
Other Expense	(31,121)
Gain on extinguishment of debt		212,258
Fair value adjustments on convertible notes payable		(1,866,922)
Loss before income taxes	(7,916,018)	(8,151,654)
Income tax expense	(20,993)	(2,459)
Net loss	$ (7,937,011)	$ (8,154,113)
Net loss per common share, basic	$ (0.91)	$ (1.81)
Net loss per common share, diluted	$ (0.91)	$ (1.81)
Weighted average common shares outstanding, basic	8,747,509	4,498,964
Weighted average common shares outstanding, diluted	8,747,509	4,498,964

BIAF Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 2,821,570	$ 11,413,759
Accounts and other receivables, net	811,674	10,489
Inventory	18,484	5,540
Prepaid expenses and other current assets	321,017	531,899
Total current assets	3,972,745	11,961,687
Non-current assets:
Property and equipment, net	458,633	214,438
Operating lease right-of-use asset, net	370,312
Finance lease right-of-use asset, net	1,165,844
Goodwill	1,404,486
Intangible assets, net	833,472
Other assets	16,060	6,000
Total assets	8,221,552	12,182,125
Current liabilities:
Accounts payable	604,789	345,042
Accrued expenses	1,149,811	541,894
Unearned revenue	33,058
Operating lease liability, current portion	94,708
Finance lease liability, current portion	365,463
Loan payable		251,746
Total current liabilities	2,247,829	1,138,682
Non-current liabilities
Operating lease liability, net of current portion	283,001
Finance lease liability, net of current portion	835,467
Total liabilities	3,366,297	1,138,682
Commitments and contingencies (See Note 10)
Stockholders’ equity:
Preferred stock, no shares issued or outstanding at December 31, 2023 and 2022, respectively
Common stock, par value $0.007 per share; 25,000,000 and 14,285,714 shares authorized; 9,394,610 and 8,381,324 shares issued and outstanding as of December 31, 2023 and 2022, respectively	65,762	58,669
Additional paid-in capital	49,393,972	47,652,242
Accumulated deficit	(44,604,479)	(36,667,468)
Total stockholders’ equity	4,855,255	11,043,443
Total liabilities and stockholders’ equity	$ 8,221,552	$ 12,182,125

About bioAffinity Technologies, Inc.

bioAffinity Technologies, Inc., a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat lung cancer and other diseases of the lung at the cellular level. The company was incorporated in 2014 and is based in San Antonio, Texas.

CEO	Ms. Maria Zannes J.D.
WEBSITE	bioaffinitytech.com
INDUSTRY	Diagnostics & Research
EMPLOYEES	14

bioAffinity Technologies, Inc. Frequently Asked Questions

What is the ticker symbol for bioAffinity Technologies, Inc.? What does BIAF stand for in stocks?

BIAF is the stock ticker symbol of bioAffinity Technologies, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of bioAffinity Technologies, Inc. (BIAF)?

As of Fri Apr 26 2024, market cap of bioAffinity Technologies, Inc. is 27.86 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of BIAF stock?

You can check BIAF's fair value in chart for subscribers.

What is the fair value of BIAF stock?

You can check BIAF's fair value in chart for subscribers. The fair value of bioAffinity Technologies, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of bioAffinity Technologies, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for BIAF so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is bioAffinity Technologies, Inc. a good stock to buy?

The fair value guage provides a quick view whether BIAF is over valued or under valued. Whether bioAffinity Technologies, Inc. is cheap or expensive depends on the assumptions which impact bioAffinity Technologies, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for BIAF.

What is bioAffinity Technologies, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Apr 26 2024, BIAF's PE ratio (Price to Earnings) is -3.51 and Price to Sales (PS) ratio is 11. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. BIAF PE ratio will change depending on the future growth rate expectations of investors.